STOCK TITAN

R1 RCM Inc. - RCM STOCK NEWS

Welcome to our dedicated news page for R1 RCM (Ticker: RCM), a resource for investors and traders seeking the latest updates and insights on R1 RCM.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect R1 RCM's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of R1 RCM's position in the market.

Rhea-AI Summary
R1 RCM Inc. (RCM) plans to release its financial results for the first quarter of 2024 on May 8, 2024. The company will host a conference call to discuss the results, inviting investors and interested parties to participate. A live webcast and call replay will be accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
-
Rhea-AI Summary
R1 RCM Inc. releases its 2023 Environmental, Social, and Governance (ESG) report, highlighting its commitment to corporate responsibility and sustainability. The report showcases achievements in financial counseling services, employee recognition, community support, and environmental initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
R1 RCM Inc. forms a Special Committee to evaluate strategic alternatives in response to New Mountain Capital's filing. The company aims to enhance stockholder value through careful review and consultation with independent advisors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
none
Rhea-AI Summary
R1 RCM Inc. reports strong financial performance in Q4 2023 and FY 2023 with revenue growth, net income, and adjusted EBITDA improvement. The company outlines a positive outlook for 2024, expecting revenue between $2,625 million and $2,675 million, with a focus on growth, operational discipline, and technology investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.97%
Tags
-
Rhea-AI Summary
Coliseum Capital Management, LLC expresses dissatisfaction with the offer made by New Mountain Capital, L.L.C. to acquire R1 RCM Inc. for $13.75 per share, stating it significantly undervalues the company. Coliseum supports R1 RCM's Board, management, and strategy for creating shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.14%
Tags
-
Rhea-AI Summary
R1 RCM Inc. (RCM) will present at the 2024 TD Cowen Healthcare Conference on March 4 and the 2024 Barclays Global Healthcare Conference on March 13. The live webcasts can be accessed on the Investor Relations section of R1's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
R1 RCM Inc. (NASDAQ: RCM) has been ranked number one in three Best in KLAS categories for 2024, including Ambulatory RCM Services, Government Reimbursement Services, and Underpayment Recovery Services. The company has also earned its fourth consecutive award in the Ambulatory RCM Services category. R1 has been recognized for bringing advanced automation, deep expertise, and operational performance that helped healthcare providers achieve strong financial results and enhanced patient experiences. The company's ability to integrate across multiple EHR's, maximize earned reimbursement for Medicare cost reports, and recover missed revenue opportunities make it a trusted partner in delivering comprehensive solutions that providers seek.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
none
-
Rhea-AI Summary
R1 RCM Inc. (NASDAQ: RCM) has entered a 10-year partnership with Providence, a leading health system, to provide comprehensive revenue cycle services. The company also announced the completion of the acquisition of Acclara from Providence and plans to release its fourth-quarter and full-year 2023 financial results and 2024 outlook on February 27, 2024. The acquisition is expected to contribute more than $625 million in revenue and approximately $185 million to Adjusted EBITDA by year five of the partnership. R1 acquired Acclara for $675 million in cash and a warrant to purchase up to 12.2 million shares of R1 stock at a strike price of $10.52.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.79%
Tags
-
Rhea-AI Summary
R1 RCM Inc. (NASDAQ: RCM) expects fourth quarter revenue of approximately $563 to $567 million, GAAP Operating income of $36 to $39 million, GAAP net loss of $8 to $10 million, and adjusted EBITDA of $163 to $166 million. The company anticipates a 6 to 6.5 percent increase in revenue compared to the prior year. R1 RCM will report its 2023 financial results on February 27, 2024, and will provide details on its 2024 outlook at that time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
Rhea-AI Summary
R1 RCM Inc. (NASDAQ: RCM) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
conferences
R1 RCM Inc.

Nasdaq:RCM

RCM Rankings

RCM Stock Data

5.25B
291.50M
1.09%
104.14%
2.85%
Health Information Services
Healthcare
Link
US
Chicago

About RCM

R1 RCM Inc. is an American revenue cycle management company servicing hospitals, health systems and physician groups across the United States.